## Drug Summary
Gliquidone, marketed under various brand names such as Devotan, Fordiab, and Glurenorm, is a sulfonylurea class medication primarily used in the treatment of type 2 diabetes mellitus. It functions primarily as an ATP-dependent K+ channel blocker, impacting the cellular mechanisms in pancreatic beta cells. Gliquidone's action includes blocking these channels, triggering depolarization followed by activation of voltage-dependent calcium channels. This sequence leads to an influx of calcium ions, which ultimately enhances insulin release from the pancreas. Since it targets pancreatic function, it is utilized specifically in patients with non-insulin dependent diabetes mellitus (NIDDM), helping to lower blood glucose levels by amplifying both the production and the release of insulin.

## Drug Targets, Enzymes, Transporters, and Carriers
Gliquidone acts on specific molecular targets to exert its therapeutic effects. It influences the ATP-binding cassette sub-family C member 8 (ABCC8) and the ATP-sensitive inward rectifier potassium channel 8 (KCNJ8). These targets are involved in the regulation of potassium channels in pancreatic beta cells which play a crucial role in the cellular mechanisms underlying insulin secretion. Furthermore, it is metabolized by the enzyme Cytochrome P450 2C9 (CYP2C9), a key enzyme in the biotransformation of various substances in the liver. However, details regarding specific transporters and carriers are not provided, and there is apparently no significant involvement of these components in its pharmacokinetic profile as per the available data.

## Pharmacogenetics
Gliquidone's pharmacogenetic profile involves its metabolism, which is significantly impacted by genetic variations in the CYP2C9 enzyme. Variants in the CYP2C9 gene can alter enzyme activity, potentially affecting the drug's metabolism and overall effectiveness or risk of adverse effects. Since CYP2C9 is known to exhibit polymorphism in the population, individuals carrying certain genetic variants may have altered glycaemic control or a different risk profile for hypoglycemia when treated with gliquidone. The pharmacogenetic implications for gliquidone highlight the importance of considering genetic makeup when prescribing this medication to optimize therapeutic outcomes and minimize risks.